Pliant Therapeutics Inc Review Data from the 320 mg Group of the INTEGRIS-IPF Phase 2a Trial of Bexotegrast (PLN-74809) in Patients with IPF Call Transcript
Dear ladies and gentlemen, thank you for standing by. Welcome to the Pliant Therapeutics webcast to review data from the INTEGRIS-IPF Clinical Trial of Bexotegrast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker host, Christopher Keenan, Vice President of Investor Relations. Please go ahead.
Thank you, Olivia, and good morning, everyone. Thank you for joining us for Pliant's presentation of data from the INTEGRIS Phase 2a clinical trial evaluating bexotegrast at 320 milligrams in patients with idiopathic pulmonary fibrosis.
The press release referenced during this call was issued yesterday and is available under the Investors & Media section of our corporate website. The slides accompanying this webcast presentation are now available under the Events
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |